Johnson & Johnson Gain FDA Approval For New Booster Shot That Is 79% More Effective at Causing Blood Clots

0
Johnson & Johnson Gain FDA Approval For New Booster Shot That Is 79% More Effective at Causing Blood Clots
geralt / Pixabay

Johnson & Johnson (NYSE:JNJ) is yet again making headlines after the pharmaceutical company was granted FDA approval for their new booster shot.

Get Our Activist Investing Case Study!

Get the entire 10-part series on our in-depth study on activist investing in PDF. Save it to your desktop, read it on your tablet, or print it out to read anywhere! Sign up below!

Q3 2021 hedge fund letters, conferences and more

Li Lu And Greenwald On Competitive Advantages And Value Investing

Li LuIn April, Li Lu and Bruce Greenwald took part in a discussion at the 13th Annual Columbia China Business Conference. The value investor and professor discussed multiple topics, including the value investing philosophy and the qualities Li looks for when evaluating potential investments. Q3 2021 hedge fund letters, conferences and more How Value Investing Has Read More

Disclaimer: This is a satirical article.

Johnson & Johnson Shares Soar On Its Booster Shot News

Johnson & Johnson boasted about its lack of safety, citing “We out did ourselves with this one. Our new booster shot is now 79% more likely to cause blood clots, as to our previous jab which only had a roughly 32.5% chance at giving one a blood clot.”

Johnson & Johnson shares soared on the good news.

This post first appeared on The Stonk Market


Disclaimer: This is a satirical article.

Updated on

No posts to display